Lepu Biopharma Co., Ltd. (SEHK: 2157)
Health Care · Biotechnology · CN
HK$3.82
-5.56% today · -44.2% 1Y
Lepu Biopharma Co., Ltd. (SEHK: 2157) operates in the Biotechnology industry within the Health Care sector. The company is valued at $878.35M and employs 646 people.
Over the last twelve months the share price has lost 44.2%, trading between 3.55 and 7.32.
Tweenvest scores Lepu Biopharma Co., Ltd. across four factors: quality 41/100, value 49/100. Its strongest factor is value.
2157 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $878.35M
- Revenue (TTM)
- $145.94M
- P/E
- 24.14
- EPS
- 0.14
- Dividend yield
- —
- Beta (5Y)
- -0.39
- 52-week high
- HK$7.32
- 52-week low
- HK$3.55
- Avg volume (3M)
- —
- Shares outstanding
- 1.80B
- Employees
- 646
- Next earnings
- —
About Lepu Biopharma Co., Ltd.
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
- ISIN
- CNE100004SM4
- Founded
- 2018
- Listed since
- Feb 23, 2022
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Frontier Biotechnologies Inc.SHSE: 688221 | $886.38M | CN¥15.85 | -6.05% |
| Corvus Pharmaceuticals, Inc.NasdaqGM: CRVS | $884.95M | $10.04 | -4.56% |
| Beijing SL Pharmaceutical Co., Ltd.SZSE: 002038 | $883.46M | CN¥5.76 | +0.17% |
| Monte Rosa Therapeutics, Inc.NasdaqGS: GLUE | $878.73M | $10.54 | +2.28% |
| Kuros Biosciences AGSWX: KURN | $878.10M | CHF18.78 | +2.34% |
| PeptiDream Inc.TSE: 4587 | $872.86M | ¥1,075.00 | +2.14% |
| Hangzhou Biotest Biotech Co.,Ltd.SHSE: 688767 | $865.08M | CN¥39.60 | -1.49% |
| Sana Biotechnology, Inc.NasdaqGS: SANA | $835.22M | $2.62 | -6.09% |
Figures last refreshed Oct 11, 2026.